Skip to content
Review Open access

Chronic kidney disease and cognitive decline: choroid plexus remodeling, glymphatic dysfunction, and Alzheimer biomarker interpretation

Sep 2026 · Neurological Sciences · Vol 47 · 0 citations · 49 references
Medicine

Abstract

Cognitive impairment is common in chronic kidney disease (CKD), yet vascular, uremic, dialysis-related, and neurodegenerative mechanisms are often considered separately. We propose an integrated kidney–brain tissue-environment framework to support neurological interpretation of cognitive, imaging, and biomarker findings in CKD. We conducted a narrative synthesis of clinical, neuroimaging, experimental, and biomarker studies retrieved from PubMed/MEDLINE, Embase, Scopus, and Web of Science through June 2026, focusing on barrier dysfunction, choroid plexus remodeling, cerebrospinal fluid dynamics, neurovascular coupling, white-matter injury, glymphatic-related imaging markers, and Alzheimer disease-related plasma biomarkers. CKD is associated with convergent vascular, inflammatory, toxic, barrier, and neurofluid-related abnormalities that may contribute to a mixed cognitive phenotype. Human studies report choroid plexus enlargement, lower diffusion tensor image analysis along the perivascular space (DTI-ALPS) indices, altered cerebrospinal fluid-related signal coupling, and neurovascular decoupling; however, evidence is predominantly cross-sectional and does not establish temporal or causal sequencing. Choroid plexus enlargement is morphologically nonspecific, while DTI-ALPS reflects a composite tissue environment rather than direct glymphatic flow. Reduced kidney function may also increase plasma phosphorylated tau, amyloid-β, neurofilament light chain, and glial fibrillary acidic protein concentrations. Ratio-based measures may attenuate, but do not uniformly eliminate, kidney-related confounding. CKD should be regarded as an active modifier of cognitive phenotype, neuroimaging interpretation, and plasma biomarker assessment. The proposed framework is testable rather than causal and supports reporting kidney function, dialysis context, and multimodal markers when evaluating cognitive decline.

Read PDF

Similar papers

Open access Sep 2026

Regional choroid plexus calcifications and their associations with aging, brain structure, and disease

QSM-derived CPcal is a scalable, radiation-free imaging phenotype that complements volumetry by characterizing calcific CP tissue, which is associated with cardiometabolic health, brain aging, and neurodegenerative risk, particularly in the third ventricle.

Iyad Ba Gari, Alyssa H. Zhu, Ravi R. Bhatt et al. · 0 citations
Review Open access Sep 2026

From Cognitive Impairment to Uremic Encephalopathy in Chronic Kidney Disease: A Proposed Pathophysiological Continuum

Chronic kidney disease (CKD) is associated with neurological abnormalities ranging from subtle cognitive deficits to acute or subacute uremic encephalopathy. Although clinically distinct, these syndromes may arise from overlapping biological processes, including retained uremic solutes, cerebrovascular and blood–brain...

Jelena Nesović Ostojić, Andrija Vuković, S. Kovačević et al. · 0 citations
Open access Oct 2026

Blood-brain barrier dysfunction and altered choroid plexus contrast kinetics in Parkinson’s disease

Neurovascular dysfunction may contribute to Parkinson’s disease (PD), but the extent and clinical relevance of blood-brain barrier alterations remain uncertain. We investigated regional blood-brain barrier permeability, fractional plasma volume, and choroid plexus contrast kinetics in patients with PD using dynam...

Sapir Fajerzstein, Gadi Maayan Eshed, Sheida Mirloo et al. · 0 citations
Review Open access Aug 2026

Biomarkers of the blood-brain barrier and the neurovascular unit and their relationship with cognitive decline and cognitive frailty.

Evidence on biomarkers associated with the blood-brain barrier (BBB) and neurovascular unit (NVU) in CD and CF support vascular and neuroinflammatory mechanisms as early, partially Alzheimer's disease-independent contributors to CD and CF, with significant modification by APOE4 and metabolic comorbidities.

Juan de Dios Rodríguez-Callejas, A. Mimenza-Alvarado, C. Lomas-Soria et al. · 0 citations
Review Open access Sep 2026

Alzheimer’s Disease in the Era of Geroscience: Mechanisms, Biomarkers, and Therapeutic Prospects

Alzheimer’s disease (AD) is the leading cause of dementia and a heterogeneous neurodegenerative disorder characterized by amyloid-β (Aβ) and tau pathology, impaired proteostasis, neurovascular dysfunction, maladaptive glial and immune responses, and synaptic dysfunction. Human genetic evidence supports an upstream role...

P. Chmielewski · 0 citations
Open access Sep 2026

Explanatory limitations of CSF, plasma, and MRI biomarkers for inflammation and blood–brain barrier disruption in dementia

The Qalb–CSF model showed the strongest inflammation-related signal, but these findings are exploratory and require validation in independent, longitudinal cohorts before an inflammation axis can be incorporated into an ATN(V)-based framework.

Azadeh Golduzian, Erik B. Erhardt, A. Caprihan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.